Pomalidomide resistance treatment

Pomalidomide is a drug commonly used to treat multiple myeloma (MM). Drug resistance refers to a pathological entity's reduced or disappeared response to the drug, resulting in reduced therapeutic efficacy. If the patient develops resistance to pomalidomide, consider changing to other types of drug combinations, such as combining other chemotherapy drugs, targeted therapy drugs, or immunotherapy drugs. This could help bypass resistance mechanisms and provide a different therapeutic pathway.

Doctors may combine pomalidomide with other medications to enhance the effectiveness of treatment. For example, pomalidomide can be used in combination with steroid drugs such as dexamethasone or prednisone to improve efficacy. Specific targeted therapy drugs are selected based on the patient's genetic mutations. These drugs can work by targeting specific mutations or abnormal signaling pathways in tumor cells. For example, if the patient has a certain mutation, specific protease inhibitors or signal transduction inhibitors may be considered.

Pomalidomide, independently developed in China, has been launched domestically and has now entered the scope of medical insurance. The price of domestically produced Pomalidomide may be around RMB 4,000 per box, while the Turkish version sold overseas may be priced around RMB 15,000 per box (the price may fluctuate due to exchange rates), which is relatively expensive. There are also cheaper generic drugs produced in other countries overseas. The price of each box produced by a Lao pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to the exchange rate). The ingredients of foreign generic drugs, domestically produced drugs and foreign original drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.